YMAB Stock Price, Y-mAbs Therapeutics Inc Quote, Chart

Market Summary

USD14.72-0.12

Delayed

-0.81%

YMAB Stock Price

View Fullscreen

YMAB RSI Chart

YMAB Valuation

Market Cap

644.4M

Price/Earnings (Trailing)

-30.07

Price/Sales (Trailing)

7.6

EV/EBITDA

-28.1

Price/Free Cashflow

-23.66

YMAB Price/Sales (Trailing)

YMAB Profitability

EBT Margin

-24.60%

Return on Equity

-21.22%

Return on Assets

-16.76%

Free Cashflow Yield

-4.23%

YMAB Fundamentals

YMAB Revenue

Revenue (TTM)

84.8M

Rev. Growth (Yr)

-25.71%

Rev. Growth (Qtr)

14.22%

YMAB Earnings

Earnings (TTM)

-21.4M

Earnings Growth (Yr)

-185.39%

Earnings Growth (Qtr)

87.25%

Breaking Down YMAB Revenue

Last 7 days

-2.7%

Last 30 days

-10.8%

Last 90 days

30.6%

Trailing 12 Months

159.1%

How does YMAB drawdown profile look like?

YMAB Financial Health

Current Ratio

5.52

YMAB Investor Care

Buy Backs (1Y)

0.11%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	75.0M	85.0M	92.9M	84.8M
2022	40.0M	39.8M	43.4M	65.3M
2021	29.2M	37.6M	46.0M	34.9M
2020	0	0	0	20.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Y-mAbs Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	tagliaferri mary	acquired	-	-	4,660	-
Mar 05, 2024	gad thomas	sold	-64,116	16.44	-3,900	chief business officer
Mar 05, 2024	smith susan laura	sold	-27,837	16.55	-1,682	svp & chief commercial officer
Mar 05, 2024	rajah vignesh	sold	-28,282	16.53	-1,711	svp & chief medical officer
Feb 12, 2024	rossi michael j	acquired	-	-	35,700	president & ceo
Jan 18, 2024	wilms joris	acquired	-	-	17,800	svp & chief operating officer
Jan 18, 2024	kruse bo	acquired	-	-	18,100	evp, cfo, secry & treas.
Jan 18, 2024	lisby steen	acquired	-	-	17,800	svp & chief scientific officer
Jan 18, 2024	smith susan laura	acquired	-	-	17,800	svp & chief commercial officer
Jan 18, 2024	gad thomas	acquired	-	-	22,100	chief business officer

Which funds bought or sold YMAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-10,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.66	1,002,620	1,820,790	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	0.74	817,535	1,400,730	0.08%
Apr 23, 2024	AMALGAMATED BANK	reduced	-70.47	-8,000	20,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	27,518	136,987	-%
Apr 22, 2024	SAPIENT CAPITAL LLC	unchanged	-	412,528	710,562	0.02%
Apr 19, 2024	DENALI ADVISORS LLC	sold off	-100	-111,848	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-313	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-32.39	117,267	308,875	0.01%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	reduced	-64.22	-357,556	2,073,980	0.01%

Are Funds Buying or Selling YMAB?

Are funds buying YMAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own YMAB

No. of Funds

Unveiling Y-mAbs Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	paradigm biocapital advisors lp	5.02%	2,198,312	SC 13G
Feb 14, 2024	wg biotech aps	10.4%	4,559,233	SC 13G/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	7.6%	3,297,800	SC 13G/A
Feb 13, 2024	vanguard group inc	5.14%	2,244,238	SC 13G/A
Feb 06, 2024	acorn bioventures, l.p.	2.7%	1,159,966	SC 13G/A
Jan 26, 2024	blackrock inc.	6.7%	2,917,080	SC 13G/A
Apr 03, 2023	acorn bioventures, l.p.	2.2%	977,142	SC 13G
Feb 14, 2023	wg biotech aps	9.6%	4,178,465	SC 13G
Feb 14, 2023	hbm healthcare investments (cayman) ltd.	8.7%	3,813,853	SC 13G/A
Feb 09, 2023	vanguard group inc	5.17%	2,258,254	SC 13G

Recent SEC filings of Y-mAbs Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	SC 13G	Major Ownership Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 08, 2024	3	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Y-mAbs Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Y-mAbs Therapeutics Inc News

Latest updates

Y-mAbs Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	14.2%	23,363,000	20,454,000	20,751,000	20,251,000	31,447,000	12,537,000	10,797,000	10,486,000	9,598,000	8,965,000	10,951,000	5,383,000	20,750,000
Costs and Expenses	-5.8%	26,562,000	28,203,000	27,974,000	27,752,000	32,600,500	38,554,000	50,742,000	38,181,000	45,356,000	37,669,000	33,663,000	33,642,000	40,844,500
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	40,844,500
S&GA Expenses	9.2%	11,135,000	10,200,000	11,270,000	12,251,000	10,793,000	13,626,000	23,082,000	13,438,000	15,138,000	13,988,000	13,475,000	11,970,000	14,630,500
R&D Expenses	-12.8%	13,388,000	15,358,000	12,055,000	13,418,000	19,787,000	22,453,000	26,420,000	22,912,000	28,757,000	23,131,000	19,778,000	21,579,000	24,011,000
EBITDA Margin	-Infinity%	-0.24	-	-1.11	-1.26	-1.45	-	-	-	-	-	-	-	-
Income Taxes	4.3%	195,000	187,000	179,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	89.5%	-793,000	-7,560,000	-6,123,000	-	-	-27,526,000	-41,131,000	-	-	-	-	-	-
EBT Margin	-Infinity%	-0.25	-	-1.12	-1.27	-1.46	-	-	-	-	-	-	-	-
Net Income	87.2%	-988,000	-7,747,000	-6,302,000	-6,390,000	1,157,000	-27,526,000	-41,131,000	-28,068,000	-36,893,000	-28,858,000	-22,937,000	33,413,000	-19,933,000
Net Income Margin	-21.7%	-0.25	-0.21	-0.46	-0.98	-1.46	-3.08	-3.39	-2.92	-1.58	-0.83	-1.12	-2.05	-5.75
Free Cashflow	-500.6%	-8,036,000	-1,338,000	-4,889,000	-13,279,000	-8,816,000	-19,390,000	-23,255,000	-25,080,000	-34,018,000	-18,147,000	-18,797,000	-32,261,000	-17,739,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.8%	128	129	132	137	141	144	165	191	213	240	259	275	132	143	167	194	216	104	126	140	152
Current Assets	-3.3%	111	115	116	124	130	133	154	178	202	231	249	264	122	133	163	190	212	100	123	137	152
Cash Equivalents	-9.2%	79.00	87.00	88.00	93.00	106	115	134	157	182	216	234	252	115	131	158	186	207	98.00	120	134	148
Inventory	-28.8%	5.00	7.00	5.00	9.00	7.00	6.00	7.00	6.00	6.00	5.00	4.00	1.00	-	-	-	-	-	-	-	-	-
Net PPE	-24.3%	0.00	0.00	0.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00
Liabilities	-6.4%	27.00	29.00	28.00	30.00	32.00	36.00	34.00	34.00	33.00	29.00	25.00	23.00	26.00	27.00	21.00	19.00	17.00	18.00	18.00	14.00	11.00
Current Liabilities	-7.7%	20.00	22.00	24.00	26.00	28.00	32.00	29.00	29.00	28.00	25.00	21.00	17.00	20.00	20.00	16.00	15.00	14.00	14.00	14.00	10.00	9.00
Shareholder's Equity	0.8%	101	100	105	108	109	108	131	157	180	211	234	252	106	117	146	175	199	86.00	108	126	141
Retained Earnings	-0.2%	-457	-456	-448	-442	-436	-437	-409	-368	-340	-303	-274	-251	-285	-265	-232	-192	-165	-142	-118	-100	-84.83
Additional Paid-In Capital	0.6%	558	555	552	549	544	540	538	524	519	514	509	504	392	382	378	367	365	229	227	226	225
Shares Outstanding	0.1%	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	42.00	40.00	-	-	-	-	-	-	-	-
Float	-	-	-	246	-	-	-	551	-	-	-	1,000	-	-	-	990	-	-	-	296	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-500.6%	-8,036	-1,338	-4,734	-13,124	-8,661	-19,235	-23,100	-24,925	-33,863	-18,076	-18,756	-31,861	-17,695	-24,145	-27,635	-21,756	-24,579	-21,395	-14,040	-13,483	-13,577
Share Based Compensation	29.6%	3,123	2,410	3,616	5,304	3,537	3,341	13,633	5,091	4,908	4,901	4,827	4,698	8,336	3,134	2,454	2,211	1,477	1,345	971	864	529
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-455	-71.00	-41.00	61,610	-44.00	-2,713	-2.00	-26.00	-1,147	-617	-75.00	-126	-
Cashflow From Financing	-	-	-	-	-	-	52.00	-	32.00	100	248	131	107,835	1,419	215	-	370	-	-	-	-	-1,842

YMAB Income Statement

2023-12-31

Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
REVENUES
Total revenues	$ 84,819	$ 65,267
OPERATING COSTS AND EXPENSES
Cost of goods sold	11,366	7,467
License royalties	50	100
Research and development	54,219	91,572
Selling, general, and administrative	44,856	60,939
Total operating costs and expenses	110,491	160,078
Loss from operations	(25,672)	(94,811)
OTHER INCOME / (LOSS), NET
Interest and other income/(loss)	4,806	(757)
LOSS BEFORE INCOME TAXES	(20,866)	(95,568)
Provision for income taxes	561	0
NET LOSS	(21,427)	(95,568)
Other comprehensive loss
Foreign currency translation	(882)	(40)
COMPREHENSIVE LOSS	$ (22,309)	$ (95,608)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.49)	$ (2.19)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.49)	$ (2.19)
Weighted average common shares outstanding, basic (in shares)	43,645,388	43,703,663
Weighted average common shares outstanding, diluted (in shares)	43,645,388	43,703,663
Product
REVENUES
Total revenues	$ 84,319	$ 49,267
License
REVENUES
Total revenues	$ 500	$ 16,000

YMAB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 78,637	$ 105,762
Accounts receivable, net	22,454	12,531
Inventories	5,065	6,702
Other current assets	4,955	5,452
Total current assets	111,111	130,447
Property and equipment, net	224	604
Operating lease right-of-use assets	1,412	1,739
Intangible assets, net	2,631	2,986
Other assets	12,491	5,680
TOTAL ASSETS	127,869	141,456
LIABILITIES
Accounts payable	6,060	14,175
Accrued liabilities	13,166	13,241
Operating lease liabilities, current portion	902	868
Total current liabilities	20,128	28,284
Accrued milestone and royalty payments	5,375	2,250
Operating lease liabilities, long-term portion	517	899
Other liabilities	864	802
TOTAL LIABILITIES	26,884	32,235
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 100,000,000 shares authorized at December 31, 2023 and December 31, 2022; 43,672,112 and 43,670,109 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	4	4
Additional paid-in capital	558,002	543,929
Accumulated other comprehensive income	449	1,331
Accumulated deficit	(457,470)	(436,043)
TOTAL STOCKHOLDERS' EQUITY	100,985	109,221
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 127,869	$ 141,456

About Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

CEO	Mr. Thomas Gad
WEBSITE	ymabs.com
INDUSTRY	Biotechnology
EMPLOYEES	147

Y-mAbs Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Y-mAbs Therapeutics Inc? What does YMAB stand for in stocks?

YMAB is the stock ticker symbol of Y-mAbs Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Y-mAbs Therapeutics Inc (YMAB)?

As of Fri Apr 26 2024, market cap of Y-mAbs Therapeutics Inc is 644.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers. The fair value of Y-mAbs Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Y-mAbs Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YMAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Y-mAbs Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether YMAB is over valued or under valued. Whether Y-mAbs Therapeutics Inc is cheap or expensive depends on the assumptions which impact Y-mAbs Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YMAB.

What is Y-mAbs Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, YMAB's PE ratio (Price to Earnings) is -30.07 and Price to Sales (PS) ratio is 7.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YMAB PE ratio will change depending on the future growth rate expectations of investors.